Pre and posttreatment evaluation of sexual function in patients with adenocarcinoma of the prostate

Eva S. Zinreich, Leonard Derogatis, Jeffrey Herpst, Georgiana Auvil, Steven Piantadosi, Stanley E. Order

Research output: Contribution to journalArticle

Abstract

Twenty-seven patients with adenocarcinoma of the prostate, and available partners, were interviewed to qualitatively and quantitatively assess their level of sexual function prior to and 12 months after radiotherapy. Assessments were made using the Derogatis Interview for Sexual Functioning (DISF). Five domains of sexual functioning are measured: sexual fantasy, arousal, experience, orgasm, and drive. Prior to therapy 17 of 27 patients (62.9%) were considered impotent. There were eight patients with a DISF score of less than 20 who were impotent. Six patients had a DISF score of greater than 47 and were considered potent. Of the patients with DISF scores between 20-47 four were potent, and nine were impotent. Post radiation therapy three of the patients considered potent (with a score greater than 47) maintained their potent status. Four patients considered impotent prior to therapy became potent after therapy. All patients with a score less than 20 prior to radiation therapy remained impotent after therapy. Results indicate that an objective evaluation of sexual function pre treatment is necessary to determine the effect of radiotherapy. Our method of qualitative assessment of sexual function was easy to implement, was reproducible and could be used to evaluate long-term effects of radiotherapy on sexual function. Of the patients presenting for radiotherapy, 62.9% were impotent. Twelve months after radiation therapy 19 of 27 (70.3%) were impotent.

Original languageEnglish (US)
Pages (from-to)729-732
Number of pages4
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume19
Issue number3
DOIs
StatePublished - 1990

Fingerprint

Prostate
Adenocarcinoma
radiation therapy
Radiotherapy
evaluation
therapy
Interviews
arousal
Orgasm
Therapeutics
long term effects
Fantasy
Arousal
pretreatment

Keywords

  • External beam irradiation
  • Pre and posttreatment potency
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Pre and posttreatment evaluation of sexual function in patients with adenocarcinoma of the prostate. / Zinreich, Eva S.; Derogatis, Leonard; Herpst, Jeffrey; Auvil, Georgiana; Piantadosi, Steven; Order, Stanley E.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 19, No. 3, 1990, p. 729-732.

Research output: Contribution to journalArticle

@article{efc58a7b2bf34e73816777c23bd252c1,
title = "Pre and posttreatment evaluation of sexual function in patients with adenocarcinoma of the prostate",
abstract = "Twenty-seven patients with adenocarcinoma of the prostate, and available partners, were interviewed to qualitatively and quantitatively assess their level of sexual function prior to and 12 months after radiotherapy. Assessments were made using the Derogatis Interview for Sexual Functioning (DISF). Five domains of sexual functioning are measured: sexual fantasy, arousal, experience, orgasm, and drive. Prior to therapy 17 of 27 patients (62.9{\%}) were considered impotent. There were eight patients with a DISF score of less than 20 who were impotent. Six patients had a DISF score of greater than 47 and were considered potent. Of the patients with DISF scores between 20-47 four were potent, and nine were impotent. Post radiation therapy three of the patients considered potent (with a score greater than 47) maintained their potent status. Four patients considered impotent prior to therapy became potent after therapy. All patients with a score less than 20 prior to radiation therapy remained impotent after therapy. Results indicate that an objective evaluation of sexual function pre treatment is necessary to determine the effect of radiotherapy. Our method of qualitative assessment of sexual function was easy to implement, was reproducible and could be used to evaluate long-term effects of radiotherapy on sexual function. Of the patients presenting for radiotherapy, 62.9{\%} were impotent. Twelve months after radiation therapy 19 of 27 (70.3{\%}) were impotent.",
keywords = "External beam irradiation, Pre and posttreatment potency, Prostate cancer",
author = "Zinreich, {Eva S.} and Leonard Derogatis and Jeffrey Herpst and Georgiana Auvil and Steven Piantadosi and Order, {Stanley E.}",
year = "1990",
doi = "10.1016/0360-3016(90)90503-C",
language = "English (US)",
volume = "19",
pages = "729--732",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Pre and posttreatment evaluation of sexual function in patients with adenocarcinoma of the prostate

AU - Zinreich, Eva S.

AU - Derogatis, Leonard

AU - Herpst, Jeffrey

AU - Auvil, Georgiana

AU - Piantadosi, Steven

AU - Order, Stanley E.

PY - 1990

Y1 - 1990

N2 - Twenty-seven patients with adenocarcinoma of the prostate, and available partners, were interviewed to qualitatively and quantitatively assess their level of sexual function prior to and 12 months after radiotherapy. Assessments were made using the Derogatis Interview for Sexual Functioning (DISF). Five domains of sexual functioning are measured: sexual fantasy, arousal, experience, orgasm, and drive. Prior to therapy 17 of 27 patients (62.9%) were considered impotent. There were eight patients with a DISF score of less than 20 who were impotent. Six patients had a DISF score of greater than 47 and were considered potent. Of the patients with DISF scores between 20-47 four were potent, and nine were impotent. Post radiation therapy three of the patients considered potent (with a score greater than 47) maintained their potent status. Four patients considered impotent prior to therapy became potent after therapy. All patients with a score less than 20 prior to radiation therapy remained impotent after therapy. Results indicate that an objective evaluation of sexual function pre treatment is necessary to determine the effect of radiotherapy. Our method of qualitative assessment of sexual function was easy to implement, was reproducible and could be used to evaluate long-term effects of radiotherapy on sexual function. Of the patients presenting for radiotherapy, 62.9% were impotent. Twelve months after radiation therapy 19 of 27 (70.3%) were impotent.

AB - Twenty-seven patients with adenocarcinoma of the prostate, and available partners, were interviewed to qualitatively and quantitatively assess their level of sexual function prior to and 12 months after radiotherapy. Assessments were made using the Derogatis Interview for Sexual Functioning (DISF). Five domains of sexual functioning are measured: sexual fantasy, arousal, experience, orgasm, and drive. Prior to therapy 17 of 27 patients (62.9%) were considered impotent. There were eight patients with a DISF score of less than 20 who were impotent. Six patients had a DISF score of greater than 47 and were considered potent. Of the patients with DISF scores between 20-47 four were potent, and nine were impotent. Post radiation therapy three of the patients considered potent (with a score greater than 47) maintained their potent status. Four patients considered impotent prior to therapy became potent after therapy. All patients with a score less than 20 prior to radiation therapy remained impotent after therapy. Results indicate that an objective evaluation of sexual function pre treatment is necessary to determine the effect of radiotherapy. Our method of qualitative assessment of sexual function was easy to implement, was reproducible and could be used to evaluate long-term effects of radiotherapy on sexual function. Of the patients presenting for radiotherapy, 62.9% were impotent. Twelve months after radiation therapy 19 of 27 (70.3%) were impotent.

KW - External beam irradiation

KW - Pre and posttreatment potency

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0024997779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024997779&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(90)90503-C

DO - 10.1016/0360-3016(90)90503-C

M3 - Article

C2 - 2211222

AN - SCOPUS:0024997779

VL - 19

SP - 729

EP - 732

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -